Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 November 2020Website:
http://www.revbiosciences.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | 7 min agoDividend
Analysts recommendations
Institutional Ownership
REVB Latest News
SAN DIEGO--(BUSINESS WIRE)---- $REVB #FDA--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced it has successfully completed the GMP manufacture of Gemini drug product to support anticipated clinical studies in the United States. GMP compliant manufacturing of Gemini is a pivotal requirement for an Investigational New Drug (IND) ap.
SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Recei.
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive topline data from.
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced safety and biomarker data for its Phase 1 clinical study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified.
What type of business is Revelation Biosciences?
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
What sector is Revelation Biosciences in?
Revelation Biosciences is in the Healthcare sector
What industry is Revelation Biosciences in?
Revelation Biosciences is in the Biotechnology industry
What country is Revelation Biosciences from?
Revelation Biosciences is headquartered in United States
When did Revelation Biosciences go public?
Revelation Biosciences initial public offering (IPO) was on 17 November 2020
What is Revelation Biosciences website?
https://www.revbiosciences.com
Is Revelation Biosciences in the S&P 500?
No, Revelation Biosciences is not included in the S&P 500 index
Is Revelation Biosciences in the NASDAQ 100?
No, Revelation Biosciences is not included in the NASDAQ 100 index
Is Revelation Biosciences in the Dow Jones?
No, Revelation Biosciences is not included in the Dow Jones index
When was Revelation Biosciences the previous earnings report?
No data
When does Revelation Biosciences earnings report?
Next earnings report date is not announced yet